Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. (Q53311940)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 July 2010

Language	Label	Description	Also known as
English	Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.	scientific article published on 16 July 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

0 references

1 reference

based on heuristic

inferred from title

Patrick F Augustijns

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

object named as

Suzanne Bal

2

0 references

Willem van Eden

8

object named as

Willem van Eden

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

13

object named as

Wim Jiskoot

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Chantal Keijzer

3

object named as

Chantal Keijzer

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

1

object named as

Bram Slütter

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

10

object named as

Clemens Löwik

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

author name string

Roel Mallants

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Niels Hagenaars

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Ivo Que

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Eric Kaijzel

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Joke Bouwstra

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

language of work or name

0 references

publication date

16 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

28

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

38

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

6282-6291

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Effective nasal influenza vaccine delivery using chitosan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Nanoparticles as carriers for nasal vaccine delivery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

PLA-PEG particles as nasal protein carriers: the influence of the particle size.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Rational design of nasal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Quantifying drug release from PLGA nanoparticulates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Intranasal immunization against influenza virus using polymeric particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Chitosan-based delivery systems for protein therapeutics and antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Evaluation of mucoadhesive PLGA microparticles for nasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Effect of preservatives on ciliary beat frequency in human nasal epithelial cell culture: single versus multiple exposure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

High-speed digital imaging method for ciliary beat frequency measurement.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Cell biology of antigen processing in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.121

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.06.121

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20638455

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53311940&oldid=2150513066"